Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18
Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

Related Posts
Creating Images Via AI? Google Launches Tools To Detect Fake Images And Curb Misinformation
May 15, 7:39 AM
Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG) plans to add new features to its Image Search tool to help users find the authentic source of an image in a bid to identify misleading AI pictures.
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 3, 2:23 PM
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Housing Market Correction: Rates Up, Lack Of Buyers, Cracks Forming In Home Improvement
March 1, 1:03 PM
The housing market, still in its relentless rough patch as mortgage rates continue to climb higher, is deterring buyers from making a move.